| Martha Andrade Mclemore, LCSW | |
|
1360 E Lassen Ave, Chico, CA 95973-7823 | |
| (530) 267-1762 | |
| Not Available |
| Full Name | Martha Andrade Mclemore |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1360 E Lassen Ave, Chico, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013143866 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 1041C0700X | Social Worker - Clinical | 29339 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Martha Andrade Mclemore, LCSW 1265 Banning Park Dr, Chico, CA 95928-3820 Ph: (530) 514-7044 | Martha Andrade Mclemore, LCSW 1360 E Lassen Ave, Chico, CA 95973-7823 Ph: (530) 267-1762 |
News Archive
At least one person in ten has a negative attitude to bowel cancer screening, particularly those from South Asian backgrounds, says research published in the British Journal of Cancer.
The Obama Justice Department has been taking a more aggressive approach against people who block access to abortion clinics, using a 1994 law to bring cases in greater numbers than its predecessor. The numbers are most stark when it comes to civil lawsuits, which seek to create buffer zones around clinic entrances for people who have blocked access in the past.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food & Drug Administration has extended the Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indication of Takeda's investigational biologic, vedolizumab.
In a study of people with mild cognitive impairment (MCI), those who took the drug donepezil were at reduced risk of progressing to a diagnosis of Alzheimer's disease (AD) during the first year of the trial, but by the end of the 3-year study there was no benefit from the drug. Vitamin E was also tested in the study and was found to have no effect at any time point in the study when compared with placebo.
Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.
› Verified 1 days ago